Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.03
-0.0600-5.50%
Post-market: 1.030.00000.00%18:49 EDT
Volume:7.30M
Turnover:7.60M
Market Cap:348.67M
PE:-4.04
High:1.10
Open:1.09
Low:1.01
Close:1.09
52wk High:2.73
52wk Low:0.9700
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.94
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-21.06
PE(LYR):-4.56

Loading ...

Ocugen Inc. Stock Sheds 5.5%, Underperforms Market

Dow Jones
·
2 hours ago

Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target

TIPRANKS
·
Yesterday

Ocugen to Present 12-Month Phase 2 ArMaDa Trial Results for Ocu410 Gene Therapy in Geographic Atrophy at AAO 2026

Reuters
·
Yesterday

Ocugen to Participate in Upcoming Scientific Conferences

GlobeNewswire
·
Yesterday

Ocugen Inc. Stock Rallies 5.8%, Outperforms Market

Dow Jones
·
Yesterday

Ocugen CEO Musunuri Moderates H.C. Wainwright Biotech on Tap Panel

Reuters
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
Sep 26

Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas

Dow Jones
·
Sep 25

Ocugen Wins Provisional Approval for Ocu400 in Bahamas Under LARTA Pathway

Reuters
·
Sep 25

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in the Bahamas to Provide Ocu400 to Patients for Treatment of Retinitis Pigmentosa

THOMSON REUTERS
·
Sep 25

Ocugen Inc. Stock Slips 3.8%, Underperforms Market

Dow Jones
·
Sep 24

Ocugen Stockholders Meeting Draws Quorum with 160,214,431 Shares Represented

Reuters
·
Sep 23

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Sep 22

H.C. Wainwright Reaffirms Their Buy Rating on Ocugen (OCGN)

TIPRANKS
·
Sep 22

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
Sep 18

Ocugen: Buy Rating Maintained as Analyst Sees Upside Potential in OCU410ST Trial and Keeps $8 Price Target Unchanged

TIPRANKS
·
Sep 17

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

Ocugen CEO Shankar Musunuri Sells Common Shares Worth $589,430.24

Reuters
·
Sep 12

Ocugen Inc. Stock Slips 3.8%, Underperforms Market

Dow Jones
·
Sep 11